Tuesday, June 26, 2012

New NEA blog post, on repurposed skin barrier drug for eczema

See my new post on the website of the National Eczema Association. It's about researchers at the University of Rochester who are conducting a clinical trial of Actos, a drug originally developed to treat diabetes but which looks like it could also repair the skin barrier and help eczema patients.

I learned about Actos when I spoke to Alice Pentland, who directs the new Skin Barrier Research Consortium at Rochester. I was going to write about the consortium but got too excited about Actos instead. I'll have to cover the research group in a second post.

2 comments:

  1. This comment has been removed by a blog administrator.

    ReplyDelete
  2. I should note that it's illegal (and, if prosecuted, extremely expensive) for drug companies to promote off-label scrips for uses not approved by the FDA. See the NYT story today about Glaxo's $3 billion (!!!) fine for promoting Paxil and Wellbutrin.

    http://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?_r=1&hp

    ReplyDelete